2018 Hepatitis Drug Development Pipeline Review - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jul 6, 2018--The “Hepatitis Drug Development Pipeline Review, 2018” report has been added to ResearchAndMarkets.com’s offering.
This report provides an overview of the pipeline landscape for hepatitis infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hepatitis A, hepatitis B, hepatitis D and hepatitis E, and features dormant and discontinued products.
Hepatitis refers to inflammation of the liver and is most commonly caused by viral infections. Hepatitis A and E are typically caused by ingestion of contaminated food or water. Symptoms of hepatitis A infection include fatigue, nausea and vomiting, loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes.
Risk factors include a weakened immune system and use of injected or non-injected illicit drugs. Symptoms of hepatitis E include yellowing of the skin, dark urine, fever, fatigue, joint pain, nausea, a loss of appetite and pain in the abdomen.
Hepatitis B and hepatitis D infection typically occur as a result of contact with infected body fluids. Transmission of hepatitis B can occur via sexual contact, injection drug use or transfusions of contaminated blood and blood products. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes, dark urine, extreme fatigue, nausea, vomiting and abdominal pain.
Hepatitis D infection only occurs in persons previously infected with hepatitis B, as the hepatitis D virus can only replicate in the presence of hepatitis B. The co-infection of hepatitis B and hepatitis D is associated with greater disease severity than hepatitis B infection alone.
Companies FeaturedAbivax SA AiCuris GmbH & Co KG Aucta Pharmaceuticals LLC Beijing Kawin Technology Share-Holding Co Ltd Bukwang Pharm Co Ltd Cocrystal Pharma Inc CyTuVax BV DelSiTech Ltd Dicerna Pharmaceuticals Inc Dong-A Socio Holdings Co Ltd Ensemble Therapeutics Corp GC Pharma Gilead Sciences Inc GlaxoSmithKline Plc Intellia Therapeutics Inc Ionis Pharmaceuticals Inc ISA Pharmaceuticals BV Jiangsu Hansoh Pharmaceutical Group Co Ltd Johnson & Johnson Kainos Medicine Inc Kineta Inc LG Chem Ltd Microbiotix Inc MultiCell Technologies Inc Oncolys BioPharma Inc Pfenex Inc Rodos BioTarget GmbH Samjin Pharm Co Ltd Sanofi Pasteur SA Spring Bank Pharmaceuticals Inc TCM Biotech International Corp Theravectys SA VBI Vaccines Inc VLP Biotech Inc and many more...
Key Topics Covered
1 Table of Contents
3 Therapeutics Development
4 Therapeutics Assessment
5 Companies Involved in Therapeutics Development
6 Dormant Projects
7 Discontinued Products
8 Product Development Milestones
For more information about this report visit https://www.researchandmarkets.com/research/kk9fhh/2018_hepatitis?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180706005139/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Drug Discovery,Infectious Diseases Drugs,Liver and Kidney Disorders Drugs
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 07/06/2018 06:55 AM/DISC: 07/06/2018 06:55 AM